India currently accounts for 20 per cent of the global disease burden, higher than other emerging economies such as Mexico, Brazil, Sri Lanka and China.
India currently accounts for 20 per cent of the global disease burden, higher than other emerging economies such as Mexico, Brazil, Sri Lanka and China. While public healthcare in India has achieved several milestones such as eradication of small pox and polio, and elimination of maternal and neonatal tetanus, there is scope to do much more. India currently faces a triple burden of communicable, non-communicable and emerging infectious diseases with non-communicable diseases (NCDs) an increasing burden accounting for nearly 60 per cent of deaths annually and estimated to set back the economy by USD 4.58 trillion by 2030. Access to healthcare including awareness is limited to and restricted by a number of factors such as shortage of healthcare infrastructure, lack of trained human resources and limited health financing options; there is thus an urgent need to improve our healthcare system keeping the patient at the centre of all initiatives. This report presents the current healthcare scenario in India and the future burden, should there be a further delay in access initiatives; it also summarises the various interventions undertaken by member companies of the Organisation of Pharmaceutical Producers of India (OPPI) in this regard.
© 2017 KPMG, an Indian Registered Partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved.